Hims & Hers Health, Inc. Class A Common Stock (HIMS)
62.34
-2.31 (-3.57%)
NYSE · Last Trade: May 19th, 6:44 PM EDT
Detailed Quote
Previous Close
64.65
Open
62.80
Bid
62.13
Ask
62.18
Day's Range
61.08 - 63.61
52 Week Range
13.47 - 72.98
Volume
35,652,720
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
57,483,140
Chart
About Hims & Hers Health, Inc. Class A Common Stock (HIMS)
Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care. The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery. Read More
Large-cap stocks surged in the last week. CoreWeave, Super Micro, Coinbase, NRG Energy, Astera Labs, First Solar, Exelixis, Rocket Lab, Hims & Hers, On Holding and Gap were the top performers.
HIMS & HERS HEALTH (NYSE:HIMS) meets Minervini’s Trend Template with strong technicals and explosive earnings growth, making it a high-growth momentum candidate.
The proposal, citing a "Most Favored Nation Policy," fueled debate prompted some watchers to question the legality and feasibility of the move, while others speculated on its potential market impact.
Short interest in Hims & Hers rose to a record high of 37%, continuing a four-week climb, even as the stock surged 42% last week. The company’s quarterly revenue more than doubled, surpassing analyst expectations.
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street.
Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced the pricing of its offering of $870,000,000 aggregate principal amount of 0.00% convertible senior notes due 2030 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $450 million aggregate principal amount of notes. The issuance and sale of the notes are scheduled to settle on May 13, 2025, subject to customary closing conditions. Hims & Hers also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $130,000,000 aggregate principal amount of notes.
Hedge funds shorting Hims & Hers Health Inc (NYSE:HIMS) may regret it - earnings with a positive surprise could lead to a short squeeze as stock continues to rise, up 96% in past month.
Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced its intention to offer, subject to market and other conditions, $450 million aggregate principal amount of convertible senior notes due 2030 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Hims & Hers also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $67.5 million aggregate principal amount of notes.
